Navigation Links
Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2012 Financial Results
Date:5/7/2012

NEW YORK, May 7, 2012 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX), a biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease, today announced that a conference call will be held on Wednesday, May 9, 2012 at 8:30 a.m. EDT to discuss results for the first quarter ended March 31, 2012 and a business outlook for the remainder of 2012. Ron Bentsur, Chief Executive Officer of Keryx, will host the call.

In order to participate in the conference call, please call 1-877-869-3847 (U.S.), 1-201-689-8261 (outside the U.S.), call-in ID: KERYX. The audio recording of the conference call will be available for replay at http://www.keryx.com, for a period of 15 days after the call.

Keryx will announce its financial results for this period in a press release to be issued prior to the call.

ABOUT KERYX BIOPHARMACEUTICALS, INC.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease. Keryx is developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. The Phase 3 clinical program of Zerenex for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease is being conducted pursuant to a Special Protocol Assessment (SPA) agreement with the FDA. Keryx is headquartered in New York City.

KERYX CONTACT:
Lauren Fischer
Director - Investor Relations
Keryx Biopharmaceuticals, Inc.
Tel: 212.531.5965
E-mail: lfischer@keryx.com

 


'/>"/>
SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
2. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
3. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
4. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
5. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
6. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
7. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
8. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
9. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
10. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
11. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... 2015 CryoLife, Inc. (NYSE: CRY ), ... on cardiac and vascular surgery, announced today the appointment ... position of Senior Vice President, Operations, Quality, and Regulatory, ... to Pat Mackin , Chairman, President, and Chief ... is a seasoned industry executive with over 30 years ...
(Date:4/27/2015)... 2015   AMC Health , a leading provider ... monitored care that are transforming chronic care and population ... Conference, May 2-5 at the Los Angeles ... share information about how their innovative programs, solutions and ... personalize healthcare delivery at Booth #2116 and during their ...
(Date:4/27/2015)... , April 27, 2015 PAML announced ... collaborative agreement with Axela, Inc. to develop multiplex ... diseases. PAML is one of the nation,s leading medical ... acid and protein analysis for clinical diagnostics. ... detection strategies, and assay development serves as the ...
Breaking Medicine Technology:CryoLife Appoints William Matthews as Senior Vice President, Operations, Quality, and Regulatory 2AMC Health to Showcase Advances in Monitored Care at ATA 2015 2AMC Health to Showcase Advances in Monitored Care at ATA 2015 3AMC Health to Showcase Advances in Monitored Care at ATA 2015 4PAML and Axela Collaborate on Immune Status for Vaccine Preventable Diseases 2
(Date:4/27/2015)... OH (PRWEB) April 27, 2015 Douglas ... to help his clients feel secure, but also helps secure ... to 7 p.m., Douglas will be manning a booth at ... Center, Lausche Building, 717 E. 17th Ave., Columbus, Ohio. ... worthy event that will feature hundreds of adoptable pets from ...
(Date:4/27/2015)... Ticket Down is a reputable source ... Valley Music Theatre and the Isleta Amphitheater. ... Mexico area can celebrate because their favorite performer will ... Buffett will be performing alongside legendary performers, Huey Lewis ... during the summer and fall months of 2015 are ...
(Date:4/27/2015)... 2015 The global coagulation analyzers ... CAGR in developed countries; however, it is expected ... as China, India and Brazil in the next ... is driven by factors such as increasing adoption ... of high-throughput hemostasis analyzers, developments in high-sensitivity point-of-care ...
(Date:4/27/2015)... 2015 Volpara Solutions today announced ... the Society of Breast Imaging’s SBI/ACR Breast Imaging ... Booth #214). VolparaDensity, the first breast density ... breast tomosynthesis datasets from multiple manufacturers, is already ... and worldwide. , The latest version ...
(Date:4/27/2015)... Puroast Coffee has signed on to sponsor the ... BattleFrog OCR is a series of rigorous courses designed by ... the training that Seals undergo, as well as provide a ... to sponsor the BattleFrog events this year,” says Puroast CEO ... well-suited to give people throughout the country the chance to ...
Breaking Medicine News(10 mins):Health News:Farmers Insurance Agent Douglas Fitzpatrick Ensures Pets Find Homes 2Health News:Cheap Jimmy Buffett Tickets at Alpine Valley Music Theatre in Elkhorn, WI and at Isleta Amphitheater in Albuquerque, NM Now on Sale at TicketDown.com 2Health News:Coagulation Analyzers Market Concluded to Reach $3.58 billion by 2019 2Health News:Coagulation Analyzers Market Concluded to Reach $3.58 billion by 2019 3Health News:Volpara Solutions Releases VolparaDensity 3.1 for Use with Tomosynthesis Systems from Multiple Manufacturers at SBI 2Health News:Volpara Solutions Releases VolparaDensity 3.1 for Use with Tomosynthesis Systems from Multiple Manufacturers at SBI 3Health News:Puroast Coffee on Tour with BattleFrog 2
... Reporter , MONDAY, April 18 (HealthDay News) -- New ... stay clear of AIDS longer if they start drug ... However, starting treatment earlier, compared to waiting, didn,t ... benefit in terms of preventing death" by prescribing the ...
... , MONDAY, April 18 (HealthDay News) -- Patients with ... die after surgery, even after non-emergency procedures, a new study ... be used to revive someone who is clinically unresponsive and ... 18 and in the August print issue of the journal ...
... New research finds that older diabetics with better control of ... as heart attacks, amputation and kidney disease. However, ... sugar levels face a slightly higher chance of dying than ... normal range. Researchers tracked more than 70,000 people with ...
... , MONDAY, April 18 (HealthDay News) -- Infection with ... many college students -- and little exposure to sunlight may ... a new study suggests. "MS is more common at ... researcher, Dr. George C. Ebers, of the University of Oxford ...
... ovarian cancer (HGSOC), the fifth-deadliest cancer among American women, ... fallopian tube malignancy masquerading as an ovarian one. While ... tubes has so far been only circumstantial, a new ... connection, a finding that could aid in the development ...
... Ill. Nearly 800 dental sleep medicine professionals from ... Meeting of the American Academy of Dental Sleep Medicine ... at the Hilton Minneapolis in Minneapolis, Minn. The meeting ... 25th Anniversary Meeting of the Associated Professional Sleep Societies. ...
Cached Medicine News:Health News:Starting HIV Drugs Earlier May Delay AIDS But Not Death 2Health News:Starting HIV Drugs Earlier May Delay AIDS But Not Death 3Health News:People With DNR Orders More Apt to Die After Any Surgery 2Health News:Low Glucose Levels May Raise Death Risk Among Older People 2Health News:Can Common Virus, Lack of Sunlight Boost MS Risk? 2Health News:New scientific model tracks form of ovarian cancer to origins in fallopian tube 2Health News:New scientific model tracks form of ovarian cancer to origins in fallopian tube 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: